Opendata, web and dolomites

AXONE SIGNED

Commercial multiple electrode lead technology for cardiac disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AXONE project word cloud

Explore the words cloud of the AXONE project. It provides you a very rough idea of what is the project "AXONE" about.

revenues    pacing    effect    cardiac    prepare    industrialization    start    vein    25    time    dominated    coronary    class    leaving    patients    selling    resynchronization    leads    is4    commercial    smaller    implantation    finalize    million    2026    yearly    efficiency    direct    people    advantages    heart    clinical    manufacture    perform    single    global    commercialisation    capability    give    file    spaced    responder    generates    70    population    rate    82    sites    stimulate    place    validation    14    launch    impressive    device    confirm    depending    combines    sales    companies    previously    site    performance    vary    therapy    ventricle    2020    chronic    plan    procedure    definition    market    compete    pacemaker    axone    reducing    placed    individual    healthcare    opportunity    considerably    crt    benefits    marking    ce    marketing    finalise    times    commercialization    left    positive    initiated    medical    50    projected    decrease    diameter    generation    acute   

Project "AXONE" data sheet

The following table provides information about the project.

Coordinator
SORIN CRM SAS 

Organization address
address: AVENUE REAUMUR 4
city: CLAMART
postcode: 92140
website: www.sorin-crm.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.crm.microport.com/
 Total cost 3˙513˙187 €
 EC max contribution 2˙694˙187 € (77%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2. (PRIORITY 'Industrial leadership')
 Code Call H2020-FTIPilot-2016-1
 Funding Scheme IA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SORIN CRM SAS FR (CLAMART) coordinator 1˙373˙312.00
2    HERAEUS DEUTSCHLAND GMBH & CO KG DE (HANAU) participant 537˙687.00
3    CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN FR (ROUEN) participant 425˙062.00
4    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 358˙125.00

Map

 Project objective

Heart failure affects more than 14 million people in Europe, and is projected to affect about 30 million people by 2020. While the effects of Cardiac Resynchronization Therapy on the wider heart failure population are impressive, benefits at the individual level vary considerably. Depending on the definition, the responder rate CRT is positive in 50-70% of patients, leaving 30-50% without any significant effect. This project will finalise the development of a pacemaker cardiac lead that is 5 times smaller diameter than the state-of-the-art, and start the commercialisation of the product. The project will directly improve the efficiency of Cardiac Resynchronization Therapy (CRT) by reducing the time required for the implantation procedure by 25%, and decrease the yearly healthcare costs by 82 M€/year in Europe. In addition, the project will help European companies to compete in the pacemaker market currently dominated by US companies. Axone IS4 lead combines the advantages of a single lead, which is easy to place in any coronary vein, with the capability to stimulate the left ventricle at 2 widely spaced sites for a more global resynchronization – this has previously required 2 leads to be placed in the heart. The objective of the AXONE project is to: • Finalize product industrialization. • Confirm chronic pre-clinical performance with large scale studies. • Perform an acute clinical study and a chronic clinical validation. • Manufacture clinical and commercial products. • Build the marketing plan and prepare the product launch. • File CE marking of the class III medical device system. • Launch the commercialization of AXONE system and start selling the system in Europe. This novel approach of multi-site pacing has the potential to become the next CRT therapy device generation, initiated in Europe. This project will give an opportunity to generates 90 M€ direct revenues sales in 2026.

 Deliverables

List of deliverables.
Final acute clinical study report Documents, reports 2019-05-31 10:02:15
AXONE benefit over standard CRT report Documents, reports 2019-05-31 10:02:12
Preclinical safety performance report Documents, reports 2019-05-31 10:02:12

Take a look to the deliverables list in detail:  detailed list of AXONE deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AXONE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AXONE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.)

Innovation Principle (2019)

Developing an Innovation-Friendly Legislative Culture – the Innovation Principle at Work

Read More  

PULSe (2017)

Pervasive Ubiquitous Lightwave SEnsor

Read More  

ShaleSafe (2016)

Development of a monitoring system for inspection of soil and aquifer contamination by shalegas and fracking chemicals

Read More